HARTE-HANKS INC (HHS)
US4161962026 - Common Stock
We assign a fundamental rating of 4 out of 10 to HHS. HHS was compared to 91 industry peers in the Media industry. The financial health of HHS is average, but there are quite some concerns on its profitability. HHS has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HHS had positive earnings in the past year.
HHS had a negative operating cash flow in the past year.
In multiple years HHS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: HHS reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of HHS (-27.60%) is worse than 87.21% of its industry peers.
Looking at the Return On Equity, with a value of -141.76%, HHS is doing worse than 84.88% of the companies in the same industry.
HHS's Return On Invested Capital of 10.18% is amongst the best of the industry. HHS outperforms 89.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HHS is significantly above the industry average of 6.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.6% | ||
| ROE | -141.76% | ||
| ROIC | 10.18% |
ROA(3y)13.3%
ROA(5y)2.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)14.02%
ROIC(5y)N/A
1.3 Margins
HHS has a Operating Margin of 4.89%. This is comparable to the rest of the industry: HHS outperforms 46.51% of its industry peers.
The Gross Margin of HHS (18.72%) is worse than 81.40% of its industry peers.
HHS's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.89% | ||
| PM (TTM) | N/A | ||
| GM | 18.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y19.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HHS is creating some value.
HHS has less shares outstanding than it did 1 year ago.
HHS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HHS has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 13.05 indicates that HHS is not in any danger for bankruptcy at the moment.
HHS has a Altman-Z score of 13.05. This is amongst the best in the industry. HHS outperforms 97.67% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that HHS is not too dependend on debt financing.
HHS has a Debt to Equity ratio of 0.02. This is amongst the best in the industry. HHS outperforms 87.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.05 |
ROIC/WACC1.05
WACC9.67%
2.3 Liquidity
A Current Ratio of 1.46 indicates that HHS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.46, HHS is in line with its industry, outperforming 52.33% of the companies in the same industry.
A Quick Ratio of 1.46 indicates that HHS should not have too much problems paying its short term obligations.
HHS's Quick ratio of 1.46 is in line compared to the rest of the industry. HHS outperforms 53.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.46 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
HHS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.55%.
The Revenue has decreased by -4.67% in the past year.
HHS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)-30.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-4.67%
Revenue growth 3Y2.68%
Revenue growth 5Y-7.62%
Sales Q2Q%1.08%
3.2 Future
Based on estimates for the next years, HHS will show a very strong growth in Earnings Per Share. The EPS will grow by 40.18% on average per year.
Based on estimates for the next years, HHS will show a small growth in Revenue. The Revenue will grow by 1.68% on average per year.
EPS Next Y-729.87%
EPS Next 2Y40.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.64%
Revenue Next 2Y1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 2.81, the valuation of HHS can be described as very cheap.
HHS's Price/Earnings ratio is rather cheap when compared to the industry. HHS is cheaper than 95.35% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. HHS is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 4.97 indicates a rather cheap valuation of HHS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HHS indicates a rather cheap valuation: HHS is cheaper than 95.35% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of HHS to the average of the S&P500 Index (23.69), we can say HHS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.81 | ||
| Fwd PE | 4.97 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HHS indicates a rather cheap valuation: HHS is cheaper than 95.35% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2.51 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HHS's earnings are expected to grow with 40.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.18%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HHS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARTE-HANKS INC
NASDAQ:HHS (1/3/2025, 8:00:01 PM)
5.37
+0.27 (+5.29%)
Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)
Earnings (Next)
Inst Owners35.34%
Inst Owner Change9.8%
Ins Owners8.31%
Ins Owner Change8.67%
Market Cap39.15M
Analysts80
Price Target17.85 (232.4%)
Short Float %0.35%
Short Ratio0.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1305.94%
Min EPS beat(2)-80.2%
Max EPS beat(2)2692.08%
EPS beat(4)3
Avg EPS beat(4)743.73%
Min EPS beat(4)-80.2%
Max EPS beat(4)2692.08%
EPS beat(8)4
Avg EPS beat(8)659.83%
EPS beat(12)8
Avg EPS beat(12)512.59%
EPS beat(16)10
Avg EPS beat(16)460.86%
Revenue beat(2)0
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)-0.09%
Revenue beat(4)1
Avg Revenue beat(4)-0.55%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)4.26%
Revenue beat(8)2
Avg Revenue beat(8)-1.45%
Revenue beat(12)5
Avg Revenue beat(12)0.34%
Revenue beat(16)9
Avg Revenue beat(16)1.74%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.81 | ||
| Fwd PE | 4.97 | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.86 | ||
| P/tB | 2.32 | ||
| EV/EBITDA | 2.51 |
EPS(TTM)1.91
EY35.57%
EPS(NY)1.08
Fwd EY20.12%
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS25.73
BVpS2.89
TBVpS2.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.6% | ||
| ROE | -141.76% | ||
| ROCE | 12.88% | ||
| ROIC | 10.18% | ||
| ROICexc | 11.11% | ||
| ROICexgc | 11.87% | ||
| OM | 4.89% | ||
| PM (TTM) | N/A | ||
| GM | 18.72% | ||
| FCFM | N/A |
ROA(3y)13.3%
ROA(5y)2.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)14.02%
ROIC(5y)N/A
ROICexc(3y)17.14%
ROICexc(5y)N/A
ROICexgc(3y)17.53%
ROICexgc(5y)N/A
ROCE(3y)17.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y19.74%
F-Score3
Asset Turnover1.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.03 | ||
| Cap/Depr | 104.41% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.46 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z | 13.05 |
F-Score3
WACC9.67%
ROIC/WACC1.05
Cap/Depr(3y)132.19%
Cap/Depr(5y)105.26%
Cap/Sales(3y)1.94%
Cap/Sales(5y)1.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-729.87%
EPS Next 2Y40.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.67%
Revenue growth 3Y2.68%
Revenue growth 5Y-7.62%
Sales Q2Q%1.08%
Revenue Next Year-0.64%
Revenue Next 2Y1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.06%
OCF growth 3YN/A
OCF growth 5YN/A